Please fill out the form below and we will gladly respond as soon as possible.
On February 19, 2026, the Synovial Sarcoma Foundation brought together patients, families, clinicians, and researchers from around the world for its second community webinar—an evening focused on progress, partnership, and hope. The full webinar recording is available to watch below: The webinar was moderated by Nathan Imperiale, Chairman of the Board, and featured: Highlights Foundation […]
Synovial sarcoma is driven by a defining genetic event — the SS18-SSX fusion protein, present in nearly all cases. For years, research and therapeutic development have focused on how this fusion interacts with the SWI/SNF chromatin remodeling complex, believed to play a central role in tumor growth. However, newly published research challenges that long-standing assumption […]
A recent market analysis estimates that the global synovial sarcoma treatment market was valued at approximately $832 million in 2023 and is projected to reach $1.6 billion by 2031. While market reports focus on financial projections, they often reflect broader trends in research, drug development, and clinical trial activity. For the synovial sarcoma community, this […]
Synovial sarcoma most often develops near the large joints of the arms or legs, but in rare cases it can arise in the head and neck region. An especially uncommon presentation occurs in infants. A recently published case report describes synovial sarcoma originating in the parotid gland—the salivary gland located near the jaw and ear—in […]
Content Warning:This article references a published medical case study that includes graphic surgical images involving the head and neck region. While the information may be valuable and informative, some readers may find the images difficult to view. Please proceed with care. Synovial sarcoma most often develops in the extremities, but in rare cases, it can […]
UI Health Care has begun treating eligible patients with synovial sarcoma using a new form of immunotherapy known as T cell receptor (TCR) therapy. This treatment approach represents an important step forward in expanding access to innovative options for people facing advanced synovial sarcoma. A targeted immune-based approach TCR therapy is designed to help the […]
Researchers have studied prasterone—also known as DHEA (dehydroepiandrosterone)—as a potential treatment option for people with synovial sarcoma that has spread (metastatic) or cannot be removed through surgery. This clinical study was designed to better understand the safety of prasterone, determine appropriate dosing, and explore whether it could help slow or control disease progression. This trial […]
We are thrilled to announce a significant milestone for the Synovial Sarcoma Registry and Biospecimen Repository, as we proudly welcome our 100th registrant. This achievement signifies the growing commitment to advancing research and improving treatment options for patients with synovial sarcoma. The registry serves as a pivotal resource, collecting invaluable data and biospecimens from patients […]